Sterdex

Quick links to important sections

Sterdex

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sterdex

Quick Facts

Property Description
Active Ingredients Dexamethasone, Oxytetracycline Hydrochlorid
Form Ophthalmic ointment, Single-dose eye drops
Pharmacological Class Corticosteroid and Anti-infective Combination
Primary Action Anti-inflammatory and Antibacterial
Status Prescription-only medicine

1. What Type of Medicine is Sterdex?

Sterdex is defined as a fixed-dose combination ophthalmic preparation intended strictly for topical application to the surface of the eye. It is classified within the pharmacological group of corticosteroids and anti-infectives in combination. This classification means the medicine is specifically designed to manage conditions where both inflammation and bacterial involvement are present. The formulation is typically designated as a prescription-only medicine (Rx) due to the inclusion of the potent corticosteroid component, which requires professional assessment for safe use.

2. Composition and Forms of the Ophthalmic Preparation

The core composition features two distinct active entities: the synthetic glucocorticoid Dexamethasone and the broad-spectrum tetracycline antibiotic Oxytetracycline Hydrochlorid. Dexamethasone is clinically recognized for its ability to swiftly reduce inflammatory reactions in the eye, helping to relieve redness and swelling. The antibiotic component, Oxytetracycline Hydrochlorid, is used against a range of susceptible ocular pathogens. The medication is prepared exclusively for local use and is often supplied as an ophthalmic ointment in single-dose containers. This delivery form is advantageous as the ointment base ensures prolonged contact time on the eye's surface for sustained local action.

3. Dual Action Principle and General Therapeutic Purpose

The overall purpose of Sterdex is to provide comprehensive local management by concurrently mitigating inflammation and controlling microbial proliferation. The Dexamethasone component acts to suppress the local immune response and reduce swelling. Simultaneously, the Oxytetracycline Hydrochlorid component works to resolve bacterial issues. This strategic combination ensures that the powerful anti-inflammatory effect of the steroid is always coupled with localized infection control, managing potential threats from susceptible bacteria.

Regulatory References

  1. NIH: Dexamethasone Ophthalmic Drug Information

What side effects are possible with Sterdex?

Official Safety Profile and Documented Adverse Reactions

The safety profile of this ophthalmic combination, as classified in official regulatory documents, primarily details local eye-related reactions and serious risks associated with the corticosteroid component. Adverse reactions are grouped by frequency and affected organ system.

Adverse Reactions by Frequency

Classification Documented Reactions
Common Ocular discomfort.
Uncommon Dysgeusia (altered taste sensation).
Uncommon/Rare Blurred vision, dry eye, photophobia, eye pruritus, keratitis, conjunctivitis, increased tearing, ocular hyperemia, and abnormal sensation in the eye.
Frequency Not Known Hypersensitivity reactions, headache, dizziness, corneal erosion, and eye pain.

Serious Adverse Reactions and Systemic Risk

Official labeling documents the potential for serious ocular complications. These include Posterior Subcapsular Cataract formation and Glaucoma (ocular hypertension potentially leading to optic nerve damage), which are risks explicitly tied to prolonged administration. A critical safety constraint involves the documented risk of Perforation of the Globe when the medicine is used in the presence of diseases that cause thinning of the cornea or sclera.

Rare systemic effects, such as Cushing's syndrome and Adrenal Suppression, have been reported in post-marketing surveillance and are linked to significant systemic absorption, particularly when used in conjunction with certain inhibitors.

Duration- and Population-Specific Safety Notes

The risk of serious ocular complications, including elevated intraocular pressure, increases with the duration of therapy. Regulatory documents advise that routine intraocular pressure monitoring is required if the medicine is used for ten days or longer.

Safety notes for specific populations include the fact that the corticosteroid component is documented to be teratogenic in animal studies and is associated with an increased risk of intra-uterine growth retardation with prolonged use during pregnancy. Special caution is also noted for pediatric patients who may be more susceptible to systemic effects.

Overdose and Emergency Response

The official regulatory profile for an overdose of Sterdex, an ophthalmic combination product, focuses on two distinct areas of exposure risk. Over-application directly onto the eye surface primarily results in local toxicity, which manifests as exacerbated ocular irritation, redness, and increased tearing. This form of acute topical overdose is officially managed by flushing the eye with lukewarm water to remove excess product.

Systemic toxicity is officially classified as unlikely due to the low degree of absorption from the topical ophthalmic route. However, accidental oral ingestion of the ointment or drops mandates seeking immediate medical attention for assessment, as explicitly stated in governmental prescribing information. This action is required even when no symptoms are immediately evident.

The most serious outcomes are associated with chronic overdose, defined as intensive or prolonged use exceeding the regulated instructions. In these cases, the officially documented risks include increased intraocular pressure (IOP), which can lead to secondary glaucoma, and the potential for systemic effects like adrenal suppression from the corticosteroid component. Because of this, continuous clinical monitoring of intraocular pressure is required when prolonged overuse is suspected. Pediatric patients are noted in official documents as being particularly susceptible to these severe long-term effects. Treatment for any overdose is symptomatic and supportive, as no specific antidote is known.

Therapeutic Uses of Sterdex

What Sterdex Treats: Main Uses and Benefits

In alignment with the therapeutic framework for this category of ophthalmic combinations, this medication is commonly used in conditions presenting with systemic or localized discomfort where inflammation and a bacterial risk coexist. The medication may assist with easing the acute inflammatory reaction while supporting management of associated microbial issues.

It is generally considered relevant for symptomatic management across specific, localized lesions and conditions of the eyelids and eye appendages, including highly inflammatory styes, severe blepharitis, and the expected inflammatory reaction following eye surgery or minor trauma. This use is applied in settings where symptoms related to inflammatory or irritative states, such as pronounced redness, notable swelling, and intense irritation, create noticeable interference with functional stability.

This approach helps provide supportive relief when symptoms related to inflammation and infection interfere with routine activities. This approach helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods and assisting with supporting functional stability.


Quick Fact: Relief for Dual Symptom Load

Property Description
Symptom Focus Redness, swelling, pain, and irritation linked to acute inflammatory states.
Conditions Highly inflammatory styes, severe blepharitis, postoperative eye recovery.
Therapeutic Benefit Supports easing the acute inflammatory reaction while supporting symptomatic management of associated microbial issues.
Usage Context Short-term symptomatic assistance when dual-action management is appropriate.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sterdex — Official Regulatory Information

This section outlines the eligibility and non-eligibility profiles for Sterdex (a combination drug of Dexamethasone and Oxytetracycline) as documented in official government regulatory labels.


Populations for whom use is Contraindicated (Must Not Use):

Contraindication Type Specific Conditions
Infectious Most active viral diseases of the cornea and conjunctiva (e.g., Herpes Simplex Keratitis, Vaccinia, Varicella), Mycobacterial infections, Fungal diseases, or untreated purulent infection of the eye.
Physiological Advanced Glaucoma not controlled by medication.
Allergy Known hypersensitivity to Dexamethasone, Oxytetracycline, or any inactive ingredients in the formulation.

Populations Requiring Restricted or Conditional Use:

  • Age: Use is not established for children younger than 2 years of age. Elderly patients require close clinical supervision.
  • Ocular Comorbidities: Requires extreme caution in patients with diseases causing thinning of the cornea or sclera due to perforation risk. Use is restricted for patients with pre-existing Glaucoma or a history of Ocular Herpes Simplex.
  • Physiological Status: Use during pregnancy or lactation is conditional and only recommended if the potential benefit outweighs the documented risk to the fetus or infant.
  • Organ Function: Use has not been studied in populations with Renal or Hepatic impairment, suggesting conditional use based on professional assessment.

Regulatory documents define who can and cannot use this medicine by establishing absolute exclusions based on active infection and hypersensitivity, and by applying conditional constraints based on age, pregnancy status, and pre-existing medical conditions. This structure ensures the medicine is used only when the official label's risk profile is acceptable.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Sterdex based on its two active components and the ophthalmic route of administration. These interactions are categorized primarily by pharmacokinetic modification and administration-timing constraints.

Drug-Drug and Metabolic Interactions

Co-administration of medicines classified as strong or moderate CYP3A4 inhibitors, including specific antiretrovirals such as ritonavir and cobicistat, may interfere with the metabolism of the Dexamethasone component. This pharmacokinetic interference can reduce Dexamethasone clearance, resulting in increased systemic exposure and the potential for systemic effects from the corticosteroid. Separately, a pharmacodynamic interaction is documented with anticholinergics (such as atropine and related compounds), as simultaneous use may increase the risk of elevated intraocular pressure. These are clinically significant interactions requiring special consideration as defined in official labeling.

Administration and Population Constraints

A strict administration-timing requirement exists when Sterdex is used with other topical ophthalmic medicinal products. To ensure the best contact time for the ointment, all other preparations must be separated by a minimum of 5 minutes, and the Sterdex ointment must be administered last. Additionally, the risk of systemic effects, such as adrenal suppression from the CYP3A4-inhibitor interaction, is specifically noted to be higher in pediatric patients due to differences in metabolism and absorption, requiring heightened awareness of this interaction.

Mechanism of Action

How Sterdex Works at the Biological Level

Dual Mechanism: Anti-Inflammatory & Antibacterial Action

This combination medication exerts its effect through two distinct biological mechanisms. It employs a glucocorticoid mechanism to suppress the host's immune response and a tetracycline mechanism that inhibits the proliferation of susceptible bacteria. This dual action involves molecular targets in the host immune system and bacterial cells.


Glucocorticoid Receptor-Mediated Signal Dampening

The steroid component (dexamethasone) acts as an agonist for the intracellular Glucocorticoid Receptor (GR). This binding alters gene transcription, suppressing the expression of pro-inflammatory mediators like cytokines and prostaglandins while promoting anti-inflammatory protein synthesis. This cascade leads directly to reduced capillary permeability, inhibited leukocyte migration, and the suppression of local edema and hyperaemia.


30S Ribosomal Subunit Inhibition (Bacteriostasis)

The antibiotic component (oxytetracycline) targets the 30S ribosomal subunit within susceptible bacterial cells. By binding to this structure, the drug physically blocks the attachment of aminoacyl-tRNA, immediately halting bacterial protein synthesis. This mechanism restricts the bacteria's ability to grow and replicate (bacteriostasis), limiting the number of pathogens and targeting the bacterial component associated with the inflammation.

Dosage and Administration Information

How Sterdex is Used

This section outlines the general administration principles and dosing patterns for the fixed-dose ophthalmic preparation Sterdex (Dexamethasone and Oxytetracycline).


Administration Scope

Category Instruction
Route of administration Restricted to the Topical Ophthalmic Route, for application only to the external surface of the eye.
Dosing schedule Ointment: Apply an approximate 1/2-inch (1.25 cm) ribbon to the conjunctival sac. Drops/Suspension: Instill one or two drops per application.
Preparation requirements Ophthalmic suspension forms must be shaken well immediately prior to each use.
Age-group rules Safety and effectiveness have not been established in patients under 2 years of age.

Frequency and Duration

Standard application is typically up to four times daily (q.i.d.). For acute cases involving the drop or suspension form, the frequency may be temporarily increased to one drop every two hours during the first 24 to 48 hours.

Official use is generally intended as a short-term course, often limited to a period of 8 to 10 days. The frequency of application should be gradually reduced as signs of the condition improve. The prescription quantity is usually limited, and continuation of therapy beyond the initial specified amount requires further professional examination and re-evaluation to ensure proper oversight.


Administration Protocol

The product must be applied to the conjunctival sac of the affected eye(s). A key procedural instruction is to maintain sterility: the applicator tip must not touch the eye, eyelid, or any other surface during application. Furthermore, the instructions generally advise that contact lenses should not be worn while the medication is being used.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sterdex

Evidence for Use Following Eye Surgery

Research has explored the use of this class of medicine—a combination of a corticosteroid (Dexamethasone) and an antibiotic (Oxytetracycline)—in adults following anterior segment surgical procedures, such as cataract surgery. The studies for this combination drug class were primarily short-term, randomized trials that monitored specific clinical factors. Researchers examined outcomes related to inflammatory or irritative states, such as the speed at which inflammation cleared from the anterior chamber of the eye. They also monitored the incidence of infectious complications following surgery.

Regulatory reviews and evidence from the combination drug class suggest that this approach was studied for concurrently addressing inflammation and the risk of associated infectious issues in this short-term postoperative setting. Findings across studies for this drug class describe patterns observed in the measured outcomes and contributes to the existing literature on this drug class.

Evidence for Highly Inflammatory Blepharitis and Localized Lesions

The research base for studies evaluating this medicine in conditions involving periods of heightened symptoms, such as severe blepharitis or localized lesions like styes, is different from the postoperative setting. For these conditions characterized by fluctuating or episodic manifestations, the evidence is limited to expert consensus, regulatory positioning, and studies that utilized related combinations or monotherapies.

Research has explored short-term symptom changes in patients experiencing conditions presenting with cycles of stability and flare-ups. Studies examined patient-reported outcomes describing perceived discomfort and objective outcomes related to physical discomfort, such as the measured swelling and redness of the eyelid margins. The findings indicate that this combination was studied for use in highly inflammatory forms of these conditions, reflecting the approach to address both inflammation and potential bacterial involvement.

Gaps and Uncertainty in the Research Landscape

A primary gap in the evidence landscape for Sterdex is the reliance on the overall evidence for the drug class, rather than a large body of direct, dedicated research comparing the Dexamethasone/Oxytetracycline pairing to other treatments or placebo for every specific condition. Comparative evidence is lacking in some contexts, meaning more research is ongoing to fully contextualize the clinical role of the dual-action approach versus using a single-ingredient steroid or antibiotic. Data for populations such as pregnant or breastfeeding patients, or those with specific comorbidities, remains limited in controlled studies. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Sterdex (FAQ)


Q: Is Sterdex considered a short-term or long-term medication?

According to official regulatory information, this medicine is generally intended for a short-term course. Use is typically limited to a brief period, often cited as 8 to 10 days. Continuing therapy beyond this short period requires further professional re-evaluation.


Q: How quickly do people usually notice a change after starting Sterdex?

Studies on this type of combination drug have included examining the speed at which inflammatory conditions in the eye begin to clear. Researchers monitored objective outcomes like the reduction of swelling and redness to understand the onset of action. Regulatory information does not specify a timeline for when an individual patient should expect to see results.


Q: Is Sterdex safe to use during pregnancy according to official documents?

Official documents describe that the use of this medicine during pregnancy is only recommended if the potential benefit is assessed to outweigh the risk. Safety notes document that the corticosteroid component has been shown to be teratogenic (causing potential harm to a developing fetus) in animal studies. Use is recommended only when the potential benefit is assessed to outweigh the known risks.


Q: Are there any foods or supplements that are known to interact with Sterdex?

Regulatory documents list specific interactions with certain prescription medications, such as strong CYP3A4 inhibitors. However, official information does not document specific interactions between this ophthalmic medicine and common foods or dietary supplements.


Q: How often is Sterdex typically applied, as described in non-dosing instructions?

Regulatory documents describe the standard application frequency mentioned in the label as typically being four times per day (q.i.d.). This general frequency is part of the non-directive information provided in the product labeling, and specific directions are given by the prescribing professional.


Q: Can Sterdex cause a rebound effect when stopped?

Official instructions advise that the frequency of application should be gradually reduced as the signs of the eye condition improve. This gradual approach is standard practice with steroids and is associated with managing the risk of the treated condition worsening quickly or 'rebounding' upon immediate cessation.


Q: Why is Sterdex only available by prescription?

This medication is designated as a prescription-only medicine (Rx) primarily because it contains a potent corticosteroid component. Due to the risks associated with this type of ingredient, professional assessment and monitoring are required to ensure its safe and appropriate use.


Q: Can Sterdex cause skin discoloration?

The official safety profile focuses on local eye-related reactions. However, the corticosteroid component has been associated with side effects that can include changes in skin pigmentation when systemic absorption (absorption into the bloodstream) occurs.


Q: Can children use Sterdex?

Official regulatory documents state that the safety and effectiveness of this medicine have not been established in patients under 2 years of age. This means its use in that age group is not formally supported by the clinical evidence provided in the official labeling.


Q: Why might a doctor prescribe Sterdex instead of a different drug for the same condition?

This medicine is intended for a dual therapeutic purpose, combining anti-inflammatory and antibacterial action. It is intended for use in conditions where both inflammation and bacterial involvement are present, allowing for the concurrent management of both issues in one product.


Q: Is it normal for the treated area to feel slightly warm when first using Sterdex?

Official safety profiles list Ocular discomfort as a common adverse reaction. This general term may include transient sensations such as burning, stinging, or a feeling of warmth in the eye following application.


Q: What happens if someone accidentally uses too much Sterdex?

Official regulatory information specifies that if a large amount of the medicine is accidentally used or ingested, contacting a poison control center or seeking medical attention is required. This is standard guidance for handling exposures beyond the intended use.


Q: Does Sterdex have any warnings about driving or operating machinery?

The official safety profile lists blurred vision as an uncommon to rare side effect. Regulatory warnings are associated with this side effect and generally state that caution should be exercised when driving or operating machinery until vision is clear.


Q: What information is available about long-term research on Sterdex?

The body of clinical evidence for this drug class has largely relied on short-term studies. A primary gap noted in the evidence landscape is the reliance on evidence for the overall drug class, rather than a large body of direct, dedicated long-term research on this specific combination.


Q: Is Sterdex tested on animals?

Official safety notes confirm that the corticosteroid component was used in animal studies, by documenting that it is teratogenic (causes potential harm to a fetus) in animals.


Q: Does the official product information for Sterdex mention alcohol use?

The regulatory documents that define drug and metabolic interactions do not list alcohol use as a documented interaction for this ophthalmic preparation.


Q: Is it true that Sterdex can make my skin thinner?

Official documents describe the risk of thinning of eye structures, such as the cornea or sclera, with certain conditions. Separately, thinning of the skin is a documented systemic side effect associated with the corticosteroid component when significant systemic absorption occurs.


Q: Is Sterdex known to cause weight gain?

Weight gain is not listed as a common side effect of this localized treatment. However, it is a recognized systemic effect of corticosteroids and is associated with the systemic risk of Cushing's syndrome, which can rarely result from significant systemic absorption.


Q: What does the term 'systemic absorption' mean for a topical medicine like Sterdex?

Systemic absorption refers to the small amount of medication applied topically to the eye that may be taken up into the bloodstream. This process is important because it is what causes the risk of rare systemic effects, which are usually associated with medicines taken orally.


Q: Is Sterdex effective for common fungal infections?

Official regulatory documents list active Fungal diseases of the eye as a contraindication. This means that regulatory documents define the medicine as not to be used when these infections are present.


Q: What are the main findings from clinical trials of Sterdex?

Clinical trials for this drug class have examined specific outcomes such as the speed at which inflammatory conditions cleared from the eye. Researchers also monitored the incidence of infectious complications following surgical procedures.


Q: Why does Sterdex require gradual withdrawal in some cases?

Gradually reducing the application frequency is a practice described in the label. This approach is associated with minimizing the potential for certain systemic effects (like adrenal suppression) and managing the risk of the treated condition worsening quickly upon cessation.


Q: Is Sterdex known to interact with herbal medicines?

Regulatory documents defining drug interactions list specific interactions with certain prescription medicines (like CYP3A4 inhibitors). However, they do not document specific interactions between this combination ophthalmic product and herbal medicines.

How should Sterdex be stored and disposed of?

Storage and Handling Requirements

Sterdex (Oxytetracycline Hydrochlorid/Dexamethasone) must be stored strictly according to regulatory specifications to ensure product stability and sterility. The medication must be kept below 25 C (77 F) and must not be frozen. It requires protection from light and must be stored in its original, tightly closed container. To prevent contamination, any remaining contents of multi-dose ophthalmic preparations must be discarded after the official post-opening period, typically 28 days.

Disposal Instructions

Regulatory instructions mandate that Sterdex, whether unused or expired, must not be discarded into household waste or flushed down wastewater. All unused medicine must be returned to a pharmacy or designated collection system for disposal that complies with local pharmaceutical waste regulations. The product must always be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sterdex found in:

A-Z Index: